CYP3A4 and cancer: In light of the potential of ceritinib to increase the systemic exposure of concomitant CYP3A and 2C9 substrates at the recommended dose, a confirmatory clinical DDI study was conducted in patients with cancer to allow for a more definitive determination on dosing concomitant CYP3A and 2C9 substrates with ceritinib.